羚锐制药(600285) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,020,755,870.55, representing a 12.29% increase compared to CNY 909,046,867.70 in the same period last year[3]. - The net profit attributable to shareholders was CNY 216,817,540.12, up 13.89% from CNY 190,378,639.92 year-on-year[3]. - Basic earnings per share rose to CNY 0.383, a 12.65% increase from CNY 0.340 in the same period last year[3]. - Total operating revenue for Q1 2025 reached ¥1,020,755,870.55, an increase of 12.3% compared to ¥909,046,867.70 in Q1 2024[18]. - Net profit for Q1 2025 was ¥216,733,789.10, representing a 13.9% increase from ¥190,328,634.98 in Q1 2024[19]. - Basic earnings per share for Q1 2025 were ¥0.383, compared to ¥0.340 in Q1 2024, indicating a growth of 12.6%[20]. - The company reported a comprehensive income total of ¥223,044,911.33 for Q1 2025, compared to ¥140,894,063.49 in Q1 2024, reflecting a significant increase of 58.3%[20]. Cash Flow - The net cash flow from operating activities increased significantly by 161.91%, reaching CNY 117,615,900.12, compared to CNY 44,906,293.79 in the previous year[3]. - Cash received from sales of goods and services in Q1 2025 was ¥895,511,232.10, an increase from ¥761,878,217.97 in Q1 2024, marking a growth of 17.5%[22]. - Operating cash inflow totaled $903,232,099.55, an increase from $809,623,301.08 in the previous period[23]. - Net cash flow from operating activities reached $117,615,900.12, significantly up from $44,906,293.79[23]. - The ending cash and cash equivalents balance was $570,929,618.67, down from $1,466,278,009.71[24]. - The company experienced a net decrease in cash and cash equivalents of $657,448,187.33 during the period[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,410,895,780.92, reflecting a 7.85% increase from CNY 5,016,843,207.73 at the end of the previous year[4]. - Total liabilities rose to ¥2,067,027,296.35, compared to ¥1,936,551,143.73 in the previous period, reflecting an increase of 6.8%[14]. - The total equity attributable to shareholders was CNY 3,311,522,505.91, which is a 7.78% increase from CNY 3,072,526,287.29[4]. - Shareholders' equity increased to ¥3,343,868,484.57, up from ¥3,080,292,064.00, indicating a growth of 8.6%[15]. Investments and Acquisitions - The company approved the acquisition of 90% equity in Yingu Pharmaceutical Co., Ltd. for RMB 703,908,000, which was completed in March 2025[10]. - The company's intangible assets increased significantly from RMB 203,746,216.32 to RMB 317,123,551.29, marking an increase of approximately 55.5%[13]. - The goodwill recorded as of March 31, 2025, was RMB 482,016,236.04, indicating the company's strategic investments in acquisitions[13]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,288[8]. - The largest shareholder, Henan Lingrui Group Co., Ltd., holds 121,817,898 shares, accounting for 21.48% of the total shares, with 26,930,000 shares pledged[8]. - The company has not reported any changes in the top 10 shareholders or their participation in margin financing and securities lending activities[10]. Operating Costs and Expenses - Total operating costs for Q1 2025 were ¥780,335,122.23, up from ¥696,497,752.04 in Q1 2024, reflecting a growth of 12.0%[18]. - Research and development expenses for Q1 2025 were ¥22,799,572.17, compared to ¥20,393,113.38 in Q1 2024, showing an increase of 11.8%[19].